Loading...
•
Jun 30, 2024
Globus Medical Q2 2024 Earnings Report
Globus Medical's Q2 2024 results demonstrated strong performance, driven by the NuVasive integration, new product launches, and financial execution.
Key Takeaways
Globus Medical reported a significant increase in worldwide net sales, driven by the addition of NuVasive and increased volume in spine and enabling technology products. GAAP net income decreased due to amortization and restructuring costs, while non-GAAP EPS increased. The company raised its full-year revenue and non-GAAP EPS guidance.
Worldwide net sales increased by 115.9% to $629.7 million.
GAAP net income was $31.8 million, a decrease of 45.0% year-over-year.
GAAP diluted EPS was $0.23, while non-GAAP diluted EPS was $0.75, an increase of 20.0%.
The company raised its full year 2024 revenue guidance to $2.47 to $2.49 billion and non-GAAP diluted EPS to $2.80 to $2.90.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company raised its guidance for full year 2024 revenue to be in the range of $2.47 to $2.49 billion, and non-GAAP fully diluted earnings per share in the range of $2.80 to $2.90.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...